Photodynamic therapy (PDT) is a form of phototherapy using nontoxic light-sensitive drugs (called a photosensitizer, or simply sensitizer for short) that are exposed selectively to light, whereupon they cause targeted malignant and other diseased cells to die.
In a similar way, Sonodynamic therapy (SDT) uses therapeutic ultrasound instead of light to activate these sensitizer compounds, to provide much deeper penetration to the target cancer cells in the body.
Photodynamic therapy (PDT) and Sonodynamic therapy (SDT) may be used individually or as combined therapies depending on the disease, stage of disease, various individual circumstances or other factors which are determined by the doctor and patient. When PDT and SDT are both used for treatment the therapy is sometimes refered to as Sonophotodynamic therapy (SPDT).
sono = (ultra) sound
photo = light
PDT and SDT technology has been developing for a long time all over the world, but some parts are relatively new and the therapy is still evolving. Newer sensitisers are becoming available to target cancer cells in slightly different ways.
A light-sensitive and ultrasound-sensitive drug (called a photosensitizer) is administered intravenously, orally or topically onto the skin.
Sensitizers commonly have a chlorophyll or porphyrin ring structure which provides sensitivity to light.
Sensitizers have the characteristic of being preferentially taken up by cancer cells and diseased cells rather than by normal healthy cells.
Photosensitizers are sensitive to specific wavelengths of light and ultrasound sound waves which are absorbed by the sensitizer during the PDT and SDT treatment. In the activation process this light and ultrasound energy breaks molecular oxygen into singlet oxygen and free radicals causing damage to the cancer cells.
Photosensitizers are non-toxic and have minimal side effects.
Treatment can be continued as long as necessary while disease is present in combination with a variety of other modalities, such as GcMAF macrophage activating therapy.
Mechanism of action - Cancer cell death (Necrosis)
Sensitizing agent is selectively incorporated into cancer cells and then irradiated with red light energy and/or ultrasound energy. This causes the breakdown of molecular oxygen into singlet oxygen and free radicals in the cancer cells and leads to cancer cell death (necrosis).
Sensitizers are non-toxic and safe to use repeatedly as there is no total dose limitation.
The treatment is targeted to primarily to the tumor with minimal effect on healthy tissue.
PDT and SDT therapy does not suppress immune function. In fact quite the opposite is true. PDT and SDT is a perfect complement to immunotherapies such as GcMAF and Hyper T/NK therapy which enhance immune activity.
Vaccine-like response from immunogenic cancer cell necrosis and cancer-immune response.
The depth of light penetration limits the depth of activation.
- Sufficient light needs to reach the tumor in order to activate the breakdown of oxygen which kills the cancer cell.
- The limited depth of penetration of light is overcome by the use of ultrasound sound waves to activate the drug at deeper depths.
Ultrasound is commonly used in medicine because it safely penetrates deep into body tissues
The activation of a sensitizer using ultrasound instead of using light is called Sonodynamic Therapy (SDT).
Sonodynamic therapy, the ultrasound dependent enhancement of cytotoxic activities of certain compounds (sonosensitizers) in
studies with cells in vitro and in tumor bearing animals, is reviewed. The attractive features of this modality for cancer treatment
emerges from the ability to focus the ultrasound energy on malignancy sites buried deep in tissues and to locally activate a preloaded
sonosensitizer. Possible mechanisms of sonodynamic therapy include generation of sonosensitizer derived radicals which initiate
chain peroxidation of membrane lipids via peroxyl and/or alkoxyl radicals, the physical destabilization of the cell membrane by the
sonosensitizer thereby rendering the cell more susceptible to shear forces or ultrasound enhanced drug transport across the cell
membrane (sonoporation). Evidence against the role of singlet oxygen in sonodynamic therapy is discussed. The mechanism of
sonodynamic therapy is probably not governed by a universal mechanism, but may be influenced by multiple factors including the
nature of the biological model, the sonosensitizer and the ultrasound parameters. The current review emphasizes the effect of
ultrasound induced free radicals in sonodynamic therapy.
We are very pleased to announce we now have an Instagram account!
You can find us at @saiseimirai or simply click here to view our feed on the web . We promise to post news about Saisei Mirai and GcMAF every day, so that you are aware of all the news as well as the success of our patients.
Seminar, at Arbetets Museum, Norrkoping,Sweden, May 29
Thank you Sweden, for your kindness and warm welcome!
Dr.Toshio Inui and Dr Kentaro Kubo gave prsentation about clinical use of GcMAF (+ Oral Colostrum MAF), and Skin cell injection therapy in Norrkoping, Sweden on May 29, 2018.
2018 Integrative Medical Conference－ Vilnius, Lithuania.
Thank you very much for your participation at the Saisei Mirai 2018 Integrative Medical Conference in Lithuania, held on Saturday 26 May 2018.
We hope that you found the conference informative and worthwhile.
Your presence helped to make this event a great success and your enthusiasm and positive spirit helped make our time together both productive and fun.
We wish you all the best and hope that you continue to be with the the Saisei Mirai.
Saisei Mirai X-MAF Series activate Macrophage.
Saisei Mirai Colostrum MAF has been in development for more than 10 years.
→ Saisei Pharma
Dr. Shinichiro Akiyama held seminars for Doctors and Patients in Tifana, Mexico on Apr 09, 11, 2018.
Dr. Antonio Jimenez, Chief Medical Officer of Hope4Cancer Treatment Centers, presents "The Importance of Emotions in Cancer" at a conference in Beaumont, Texas (Jan 2018).
Dr. Antonio Jimenez presenting at the “Un Mundo Sin Cancer” (“A World Without Cancer”) conference in Barcelona, Spain (Jan 2018).
Dr. Antonio Jimenez being interviewed in the Fox News Morning Show at Beaumont, Texas (Jan 2018).
Dr.Toshio Inui gave a presentation 「QSS JAPAN TEAM Year End Seminar」 in Tokyo, Japan on Dec 23, 2017.
Dr. Toshio Inui gave presentation in Faculty of Medicine of Vilnius University in Lithuania on Nov 30, 2017. He introduced Saisei Mirai Clinic and therapy methods available at Saisei Mirai Clinic in Japan.
Dr. Toshio Inui gave presentation in Vilnius University Hospital Santaros Klinikos in Lithuania, on Nov 29, 2017. He introduced Saisei Mirai Clinic and therapy methods available at Saisei Mirai Clinic in Japan.
2017 Integrative Medical Therapies Conference - Osaka, Japan
Symposium on Integrated Medicine: Electric Fields Therapy & Immunotherapy - Jakarta, Indonesia
Dr. Toshio Inui gave a presentation of the electric field therapy and second-generation GcMAF and colostrum MAF at a conference which was held in Jakarta, Indonesia on July 22, 2016.
International Pharmacy Conference
14 to 15-JUL-2016
Dr. Shinichiro Akiyama at International Pharmacy Conference, which was held in the United States Philadelphia, Pennsylvania on July 14 to 15, 2016, the Clinical experience of colostrum derived protein against solid cancer has been announced as the Keynote Speaker.
New research papers published by Saisei Mirai in Anticancer Research available online.
New research papers published by Saisei Mirai in Anticancer Research available online.
New research papers on GcMAF and integrative cancer immunotherapy treatment written in collaboration with the University of Tokushima, Kanazawa University and Kobe University Graduate School of Medicine researchers and Saisei Mirai published in Anticancer Research journal.
Experiment report of Gc MAF stability assay
14-JUN-2012 Stability of GcMAF in Serum (PDF)
H Mukai, Y Uto. Department of Biological Science and Technology, The University of Tokushima.
The results show that 2nd Generation GcMAF is stable for 1 year at 4 °C, for 14 days at room temperature (around 20 °C), and for 7 days at 40 °C.
See Research and references for more details on experiments on macrophage phagocytic activity and stability of our GcMAF.
Collaborations with the University of Tokushima
We collaborate with GcMAF researchers at the University of Tokushima, Japan in the development of second generation GcMAF. See Research and references for published research papers on Gc-MAF in peer-reviewed scientific journals authored by the University of Tokushima researchers over the last decade. Our research on GcMAF is ongoing and papers are being prepared for publication in collaboration between the University of Tokushima and Saisei Mirai in the next few months.